nipah
viru
niv
hendra
viru
hev
zoonot
paramyxovirus
capabl
caus
sever
diseas
human
anim
virus
requir
biosafeti
level
contain
like
paramyxovirus
plaqu
reduct
neutral
test
prnt
use
detect
antibodi
surfac
glycoprotein
fusion
f
attach
g
prnt
titer
give
indic
protect
immun
unfortun
niv
hev
prnt
must
perform
contain
take
day
complet
thu
develop
neutral
assay
use
vsv
pseudotyp
particl
express
f
g
protein
niv
pvsvnivfg
target
antigen
rapid
assay
perform
evalu
use
serum
sampl
outbreak
investig
serum
sampl
experiment
niv
vaccin
studi
swine
result
neutral
assay
pvsvnivfg
antigen
show
good
correl
standard
prnt
therefor
new
method
potenti
rapid
costeffect
diagnost
method
especi
locat
lack
high
contain
facil
provid
valuabl
tool
basic
research
vaccin
develop
nipah
viru
niv
hendra
viru
hev
recent
emerg
relat
paramyxovirus
caus
sever
diseas
human
anim
virus
two
member
newli
name
genu
henipaviru
within
famili
paramyxovirida
wang
et
al
hev
emerg
australia
caus
sever
respiratori
diseas
human
hors
murray
et
al
sporad
case
hev
correspond
author
paul
rota
center
diseas
control
prevent
clifton
rd
atlanta
ga
usa
tel
fax
email
email
prota
cdcgov
disclaim
find
conclus
report
author
necessarili
repres
view
center
diseas
control
prevent
anonym
field
et
al
westburi
westburi
viru
detect
outsid
australia
first
outbreak
niv
occur
niv
occur
malaysia
singapor
manifest
respiratori
diseas
swine
fatal
febril
enceph
human
chua
et
al
niv
outbreak
occur
siliguri
india
chadha
et
al
harit
et
al
four
outbreak
niv
took
place
bangladesh
involv
patient
case
fatal
rate
hossain
et
al
malaysian
outbreak
pig
serv
amplifi
host
transmit
viru
human
chew
et
al
chua
et
al
lam
chua
paton
et
al
unlik
malaysia
mount
et
al
persontoperson
transmiss
foodborn
infect
niv
report
bangladesh
gurley
et
al
gurley
et
al
lubi
et
al
nucleotid
sequenc
studi
show
niv
strain
india
close
relat
bangladesh
malaysia
abubakar
et
al
harcourt
et
al
fruit
bat
found
main
reservoir
hev
niv
halpin
et
al
five
speci
bat
peninsular
malaysia
antibodi
niv
yob
et
al
recent
antibodi
nipahlik
virus
detect
among
bat
bangladesh
hsu
et
al
cambodia
olson
et
al
reyn
et
al
thailand
wacharapluesade
et
al
madagascar
lehl
et
al
india
epstein
et
al
china
li
et
al
ghana
hayman
et
al
widespread
distribut
fruit
bat
suggest
spillov
niv
reservoir
human
popul
could
occur
mani
countri
within
southeast
asia
subsaharan
africa
seriou
consequ
human
health
agricultur
epstein
et
al
hayman
et
al
enzymelink
immunoassay
elisa
rtpcr
use
firstlin
diagnost
test
suspect
niv
outbreak
howev
sinc
approxim
percent
fals
posit
rate
elisa
confirmatori
test
perform
use
serum
neutral
antibodi
test
neutral
test
requir
live
niv
must
perform
biosafeti
level
creat
signific
challeng
countri
lack
high
contain
facil
therefor
need
develop
altern
diagnost
method
detect
antibodi
niv
perform
condit
like
paramyxovirus
neutral
antibodi
niv
target
fusion
f
attach
g
glycoprotein
bossart
et
al
tamin
et
al
manuscript
report
develop
novel
assay
detect
neutral
antibodi
niv
target
antigen
vesicular
stomat
viru
vsv
pseudotyp
particl
pvsv
display
niv
f
g
pvsvnivfg
express
luciferas
report
gene
inhibit
entri
pseudotyp
particl
antibodi
surfac
glycoprotein
niv
detect
measur
level
luciferas
activ
follow
infect
vero
cell
infecti
niv
use
assay
perform
complet
within
hour
result
compar
favor
standard
plaqu
reduct
neutral
test
prnt
vero
cell
maintain
dulbecco
modifi
essenti
medium
dmem
contain
fetal
calf
serum
fc
lglutamin
penicillin
streptomycin
gibco
brl
product
pvsvnivfg
describ
previous
aguilar
et
al
negret
et
al
negret
et
al
experiment
niv
vaccin
base
recombin
canarypox
cp
express
either
f
cpf
g
cpg
protein
niv
describ
previous
weingartl
et
al
detail
experiment
design
vaccin
sampl
collect
schedul
describ
previous
weingartl
et
al
briefli
pig
vaccin
intramuscularli
plaqu
form
unit
pfu
high
dose
pfu
low
dose
cpf
cpg
mixtur
four
anim
per
group
condit
pig
boost
day
post
vaccin
dpv
serum
sampl
collect
anim
vaccin
day
dpv
sampl
heattreat
minut
prior
neutral
test
pvsvnivfg
pvsv
dilut
pb
ad
duplic
well
flatbottom
well
tissu
cultur
plate
incub
one
hour
plate
wash
time
pbstween
buffer
pb
tween
primari
antibodi
human
mice
dilut
block
buffer
skim
milk
pb
ad
well
incub
one
hour
plate
wash
time
pbstween
buffer
correspond
secondari
antibodi
ad
goat
antihumanhrp
goat
antimousehrp
incub
one
hour
plate
wash
time
pbstween
buffer
per
well
tmb
substrat
ad
incub
room
temperatur
minut
reaction
stop
ad
per
well
phosphor
acid
absorb
read
eia
reader
nm
tecan
inc
dilut
pseudotyp
viru
use
calcul
produc
rel
light
unit
rlu
control
well
four
fold
serial
dilut
serum
sampl
prepar
well
plate
begin
initi
dilut
minim
essenti
medium
mem
equal
volum
pvsvnivfg
ad
well
plate
incub
minut
one
hundr
microlit
pseudotyp
particleserum
mixtur
transfer
onto
well
plate
contain
monolay
vero
cell
plate
incub
co
hour
adsorpt
innocula
replac
dmem
fetal
bovin
serum
fb
penicillinstreptomycin
ps
plate
incub
co
hour
incub
medium
remov
aspir
plate
wash
twice
phosphatebuff
salin
pb
per
well
cell
lysi
detect
renilla
luciferas
perform
accord
protocol
recommend
manufactur
promega
inc
briefli
renilla
luciferas
assay
lysi
buffer
thaw
room
temperatur
dilut
ad
well
plate
place
orbit
shaker
hr
period
mechan
manipul
freezethaw
ensur
complet
lysi
cell
follow
lysi
cell
lysat
transfer
fluoroskan
ascent
fl
fluoromet
thermo
corpor
finland
preprogram
read
sec
sec
delay
renilla
luciferas
assay
reagent
ad
well
percent
inhibit
calcul
divid
averag
rlu
number
triplic
well
test
antiserum
sampl
averag
rlu
triplic
well
infect
without
antiserum
posit
control
signal
decreas
greater
consid
inhibit
titer
pvsvnivfg
neutral
assay
reciproc
highest
dilut
serum
show
higher
inhibit
serum
sampl
fail
show
least
neutral
initi
dilut
consid
neg
method
prnt
use
live
niv
describ
previous
weingartl
et
al
procedur
live
viru
perform
condit
briefli
prnt
titer
determin
base
plaqu
reduct
cutoff
start
dilut
serum
rip
assay
carri
describ
previous
tamin
et
al
singl
except
smethioninelabel
vvnivf
vvnivg
infect
cell
resuspend
ripa
buffer
sodium
deoxychol
triton
sd
mm
nacl
mm
trishcl
ph
human
serum
sampl
use
recent
outbreak
niv
bangladesh
hossain
et
al
normal
human
serum
niv
specif
hyperimmun
mous
ascit
fluid
hmaf
use
neg
posit
control
respect
ratio
antibodi
smethionin
label
lysat
infect
vero
cell
pvsvnivfg
inhibit
monospecif
antiserum
nivf
nivg
hmaf
prepar
niv
human
serum
sampl
patient
infect
niv
also
neutral
niv
standard
prnt
tabl
neg
control
serum
sampl
includ
normal
human
normal
mous
serum
monospecif
antiserum
nivn
protein
measl
viru
f
protein
tabl
result
confirm
pvsvnivfg
particl
incorpor
niv
f
g
protein
infect
particl
neutral
serum
sampl
neutral
niv
prnt
pseudotyp
particl
abl
serv
nivspecif
glycoprotein
antigen
standard
enzym
immunoassay
figur
hmaf
prepar
niv
figur
serum
mice
vaccin
vaccinia
recombin
express
niv
f
g
figur
human
serum
sampl
patient
infect
niv
figur
specif
recogn
pvsvnivfg
bound
plastic
plate
second
antibodyconjug
use
detect
mous
antibodi
gave
lower
od
read
second
antibodi
use
detect
human
antiserum
background
reactiv
pvsv
particl
use
antigen
figur
serum
sampl
recogn
surfac
glycoprotein
measl
viru
normal
human
serum
give
signal
enzym
immunoassay
format
figur
result
indic
pvsvnivfg
particl
antigen
serv
antigen
neutral
assay
enzym
immunoassay
repres
serum
sampl
pig
vaccin
cpf
cpg
cpf
cpg
recogn
nivf
niv
g
manner
consist
vaccin
scheme
figur
howev
niv
protein
detect
rip
assay
week
booster
vaccin
day
except
day
serum
sampl
pig
vaccin
cpf
cpg
figur
serum
sampl
human
infect
niv
recogn
nivg
nivf
figur
result
confirm
serum
sampl
evalu
neutral
assay
includ
antibodi
specif
surfac
glycoprotein
niv
human
serum
sampl
contain
antibodi
niv
f
g
complet
inhibit
luciferas
product
vero
cell
infect
pvsvnivfg
dilut
figur
control
serum
sampl
inhibit
luciferas
product
start
dilut
data
show
human
serum
sampl
abl
neutral
infect
pseudotyp
particl
serum
sampl
pig
vaccin
cpf
cpg
cpf
cpg
test
standard
prnt
assay
use
pvsvnivfg
antigen
figur
assay
consist
detect
neutral
antibodi
niv
serum
sampl
obtain
booster
vaccin
day
assay
base
pvsvnivfg
demonstr
high
sensit
specif
compar
standard
prnt
figur
howev
sensit
pvsvnivfg
assay
decreas
approxim
serum
sampl
collect
dpv
prnt
detect
low
level
antibodi
effici
pseudotyp
assay
rip
overal
specif
pseudotyp
assay
extrem
high
none
prevaccin
serum
sampl
posit
either
assay
figur
sampl
score
posit
neg
correl
result
pseudotyp
assay
prnt
discord
result
serum
sampl
occur
sampl
taken
dpv
figur
nearli
correl
preble
sampl
sampl
taken
dpv
compar
titer
prnt
pseudotyp
assay
gave
coeffici
correl
sampl
collect
day
serum
sampl
pig
receiv
high
dose
vaccin
overal
correl
coeffici
sampl
day
post
vaccin
respect
sever
strategi
employ
develop
new
diagnost
techniqu
detect
infect
henipavirus
emphasi
assay
requir
contain
express
system
use
produc
antigen
enzym
immunoassay
includ
niv
n
protein
yu
et
al
truncat
phosphoprotein
antigen
chen
et
al
glycoprotein
niv
eshaghi
et
al
eshaghi
et
al
eshaghi
et
al
assay
describ
use
monoclon
antibodi
immunohistochem
base
diagnosi
tanimura
et
al
xiao
et
al
modifi
plaqu
assay
plate
prepar
inactiv
gamma
irradi
stain
crameri
et
al
solubl
g
protein
andor
ephrin
coupl
bioplex
protein
array
use
measur
antibodi
respons
glycoprotein
henipavirus
bossart
et
al
pvsvnivfg
initi
develop
support
studi
identifi
cellular
receptor
henipavirus
recent
use
antigen
neutral
test
similar
approach
use
pseudotyp
particl
report
viru
particl
rvp
use
neutral
assay
sar
temperton
et
al
west
nile
viru
pierson
et
al
report
describ
first
comparison
neutral
assay
use
pvsvnivfg
prnt
vsvnivfg
neutral
assay
offer
sever
signific
advantag
prnt
assay
perform
entir
complet
less
hour
reli
autom
readout
format
instead
manual
count
plaqu
overal
result
obtain
assay
use
pvsvnivfg
consist
correl
well
result
prnt
method
figur
confirm
previou
report
abil
niv
g
induc
higher
neutral
titer
nivf
bossart
et
al
guillaum
et
al
mungal
et
al
tamin
et
al
also
pseudotyp
particl
immunogen
use
antigen
indirect
enzym
immunoassay
format
suggest
may
promis
techniqu
develop
glycoprotein
specif
enzym
immunoassay
niv
paramyxovirus
consider
variat
diagnost
method
includ
prnt
detect
low
level
antibodi
studi
result
prnt
regard
gold
standard
fifteen
discord
result
prnt
pseudotyp
neutral
assay
record
serum
sampl
collect
dpv
antibodi
level
low
one
except
prnt
titer
exceed
sampl
appear
give
fals
neg
result
pseudotyp
assay
low
titer
could
due
toxic
effect
serum
prnt
assay
five
appar
fals
posit
result
pseudotyp
assay
serum
sampl
collect
day
titer
henipavirus
zoonot
virus
natur
reservoir
fruit
bat
genu
pteropu
halpin
et
al
chua
et
al
geograph
distribut
pteropu
fruit
bat
includ
part
west
africa
south
asia
southeast
asia
pacif
island
eastern
coast
australia
vast
area
includ
heavili
popul
area
world
includ
mani
develop
countri
epstein
et
al
unlik
paramyxovirus
virus
abil
infect
wide
rang
host
speci
therefor
alway
potenti
spillov
henipavirus
natur
reservoir
human
farm
anim
good
laboratori
test
includ
serolog
viru
detect
method
need
rapidli
detect
outbreak
henipavirus
standard
firstlin
serolog
test
henipavirus
enzym
immunoassay
along
neutral
test
use
confirm
pseudotyp
neutral
assay
describ
could
use
replac
prnt
confirmatori
serolog
test
area
lack
high
contain
facil
pseudotyp
particl
could
easili
prepar
advanc
store
frozen
requir
local
laboratori
would
need
cell
cultur
capac
luminomet
new
novel
highthroughput
assay
could
also
valuabl
tool
perform
serolog
surveil
variou
bat
speci
domest
anim
final
assay
would
provid
conveni
safe
way
measur
protect
antibodi
induc
experiment
vaccin
henipavirus
pseudotyp
particl
serv
antigen
enzym
immunoassay
panel
show
reactiv
hmaf
prepar
niv
pvsvnivfg
pvsv
plate
coat
dilut
pseudotyp
particl
indic
test
enzym
immunoassay
describ
materi
method
panel
b
show
reactiv
pseudotyp
pvsvnivfg
posit
hu
neg
human
serum
sampl
sampl
mice
vaccin
recombin
vaccinia
virus
express
either
niv
f
g
antirvvnivfg
measl
h
f
antirvvchihedf
antibodi
respons
follow
experiment
vaccin
niv
figur
show
result
rip
assay
antigen
prepar
infect
vero
cell
vaccinia
virus
express
niv
f
nivg
label
smethionin
describ
materi
method
repres
serum
sampl
pig
vaccin
recombin
canarypoxviru
vaccin
express
niv
glycoprotein
cpf
cpg
cpf
cpg
dpv
use
lane
show
reaction
mock
infect
label
vero
cell
show
reaction
hmaf
prepar
niv
rip
assay
perform
describ
materi
method
analysi
serum
sampl
niv
infect
human
rip
pseudotyp
neutral
assay
panel
show
immunoprecipit
radio
label
niv
f
g
express
recombin
vaccinia
viru
human
serum
sampl
collect
outbreak
niv
sampl
nivinfect
individu
sampl
uninfect
contact
control
includ
serum
sampl
volunt
laboratori
neg
posit
control
human
serum
sampl
initi
outbreak
niv
malaysia
hum
hmaf
niv
panel
b
show
abil
serum
sampl
inhibit
luciferas
activ
vero
cell
infect
pvsvnivfg
serum
sampl
test
four
fold
dilut
begin
infect
luciferas
assay
perform
describ
materi
method
neg
comparison
result
prnt
neutral
assay
use
pvsvnivfg
antigen
graph
show
geometr
mean
titer
gmt
assay
pvsvnivfg
top
graph
prnt
lower
graph
serum
collect
dpv
pig
receiv
high
dose
vaccin
shown
sensit
specif
pseudotyp
neutral
assay
compar
prnt
figur
show
comparison
tabl
result
neutral
assay
use
vsvnivfg
prnt
serum
sampl
collect
dpv
anim
boost
day
result
pig
receiv
high
dose
low
dose
vaccin
includ
antigen
properti
vsvnivfg
pseudotyp
particl
measl
viru
f
vvmevf
describ
previous
tamin
et
al
tamin
et
al
normal
mous
serum
nm
rabbit
vaccin
pvsvnivfg
solubl
nivg
negret
et
al
negret
et
al
normal
human
serum
nh
serum
human
infect
niv
hs
pig
vaccin
canarypox
vector
alon
cp
recombin
virus
express
nivf
nivg
weingartl
et
al
